ezetimibe / Generic mfg. - LARVOL DELTA

DRUG INDUCED TUBULOINTERSTITIAL NEPHRITIS WITH FANCONI SYNDROME POSSIBLY LINKED TO ROSUVASTATIN: A CASE REPORT (ISN-WCN 2026) - "However, there was widespread infiltration of inflammatory cells and tubulitis in the tubulointerstitial area, leading to the diagnosis of tubulointerstitial nephritis.Results Oral prednisolone (40 mg/day) was initiated, which resulted in a marked improvement in renal function. Although there have been a few reports on statin-related interstitial nephritis, the concurrence of Fanconi syndrome has not been documented. The favorable outcomes following drug discontinuation, corticosteroid therapy, and a safe switch to ezetimibe highlight the importance of early diagnosis and appropriate management of this condition."

Case report • Clinical • Anorexia • Cardiovascular • Dyslipidemia • Hypertension • Immunology • Infectious Disease • Metabolic Disorders • Nephrology • Respiratory Diseases

A CASE OF LIPOPROTEIN GLOMERULOPATHY WITH APOE SENDAI VARIANT SUCCESSFULLY MAINTAINED WITHOUT PROGRESSION FOR EIGHT YEARS UNDER PEMAFIBRATE-BASED THERAPY (ISN-WCN 2026) - "Since proteinuria persisted, additional ARB, eicosapentaenoic acid (EPA), an SGLT2 inhibitor, and ezetimibe were introduced...Although bezafibrate has been reported to be effective in some cases, in this case, renal function had already declined at diagnosis, and bezafibrate was contraindicated. This is a rare case of LPG with APOE Sendai mutation in which renal function was preserved for eight years under pemafibrate-based therapy. Pemafibrate may represent a safe and effective treatment option for patients with LPG and renal impairment."

Clinical • Cardiovascular • Glomerulonephritis • Hematological Disorders • Ischemic stroke • Rare Diseases • Thrombosis • APOE

Lowering of Lipoprotein(a) with Olpasiran. (PubMed, Cardiovasc Hematol Disord Drug Targets) - "Ezetimibe, which inhibits cholesterol absorption and can reduce LDL-C, does not significantly affect Lp(a) levels, even when used in combination with statins. In this review article, we delve further into lowering of Lp(a) with Olpasiran by detailing its pharmacological properties, its efficacy based on data from clinical trials, and ongoing research. The study also contextualizes it within the broader therapeutic landscape alongside other agents targeting Lp(a), such as Pelacarsen and Lepodisiran."

Journal • Atherosclerosis • Cardiovascular • Myocardial Infarction

Management of lipid profile and lipid-lowering therapy in the diabetic population of a primary care center according to cardiovascular risk category (SCORE2-Diabetes vs. SCORE). (PubMed, Rev Port Cardiol) - "Lipid-lowering therapy remains underutilized in patients with type 2 diabetesTYPE 2 DIABETES, particularly those at high and very high CVR, as over half fail to achieve LDL-C targets. Notably, the SCORE model appears to overestimate CVR compared with SCORE2-Diabetes."

Journal • Cardiovascular • Diabetes • Metabolic Disorders • Renal Disease • Type 2 Diabetes Mellitus

Modulation of oxidation-related immune markers by lipid-lowering medications in individuals with elevated lipoprotein(a). (PubMed, Clin Res Cardiol) - "In individuals with Lp(a) levels ≥ 75 nmol/L, high-intensity statins, add-on ezetimibe and add-on PCSK9i reduced IgG apoB-IC but did not affect IgM apoB-IC, or IgG and IgM anti-MDA-mimotope levels. The clinical significance of these findings warrants further investigation."

Journal • Atherosclerosis • Cardiovascular • APOB

Exploratory observational study with Two-year outcomes of early in-hospital evolocumab in acute coronary syndrome patients undergoing coronary artery bypass grafting. (PubMed, Front Cardiovasc Med) - "All received high-intensity statin therapy ± ezetimibe (STANDARD, n = 43), while 31 also received evolocumab 140 mg every two weeks (EVOLOCUMAB), initiated pre-angiography, preoperatively, or within 72 h post-CABG. Given the retrospective observational design, causal inference is limited and residual confounding cannot be excluded. These findings are hypothesis-generating and require confirmation in randomized trials."

Journal • Observational data • Acute Coronary Syndrome • Cardiovascular • Myocardial Infarction

Moderate-intensity statin plus ezetimibe: time to rethink it as an optimal initial lipid-lowering strategy (PubMed, Zhonghua Xin Xue Guan Bing Za Zhi) - No abstract available

Journal • Review

Association of Cardiovascular Outcomes with Bempedoic Acid vs. Ezetimibe Added to Moderate-Intensity Statin Therapy in People with Type 2 Diabetes (ADA 2026) - "Available on Friday, May 29, 2026 at 12:00am CDT."

Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

DUAL SHIELD AGAINST CADMIUM NEUROTOXICITY: EZETIMIBE AND SERICIN ATTENUATED SYNAPTIC PLASTICITY IMPAIRMENT (ADPD 2026) - "In conclusion, ezetimibe and sericin demonstrate promising neuroprotective effects against cadmium-induced neurotoxicity, supporting their potential as therapeutic candidates in the management of Cd²⁺-induced neurotoxicity."

Cognitive Disorders • Inflammation • Mood Disorders • IGF1

HOW LOW CAN WE GO: TRENDS IN CHOLESTEROL MANAGEMENT AFTER CORONARY REVASCULARIZATION ACROSS A MUTLI-CENTER HEALTH SYSTEM (ACC 2026) - "Groups with LDL≥ 100, ≥70, and ≥55 had a greater use of ezetimibe and evolocumab. Those with more cardiovascular risk factors identified were able to achieve lower LDL levels. Those with higher LDL levels had a greater prevalence of additional therapies beyond statins. This calls for further investigation into why physicians are more successful in achieving lower LDL in individuals with medical conditions that heighten cardiovascular risk."

Cardiovascular • Chronic Kidney Disease • Dyslipidemia • Nephrology

UNVEILING FAMILIAL SITOSTEROLEMIA: A SILENT CULPRIT BEHIND HYPERLIPIDEMIA IN AN ASYMPTOMATIC 28 YEAR-OLD MALE (ACC 2026) - "Decision-Making: Atorvastatin 80 mg was initiated but reduced to 40 mg due to myalgias, and ezetimibe was added...A trial of evolocumab, a PCSK9 inhibitor, was ineffective (LDL 455 mg/dL)... FS should be considered in young patients with refractory hyperlipidemia. Genetic testing and targeted therapy with ezetimibe, alongside dietary phytosterol restriction, can achieve significant LDL reduction and prevent cardiovascular complications."

Coronary Artery Disease • Dyslipidemia • Hypertension • Metabolic Disorders • Musculoskeletal Pain

LACK OF RESPONSE TO INCLISIRAN IN HIGH-RISK PATIENTS WITH ADVERSE EFFECTS TO TRADITIONAL LIPID-LOWERING THERAPIES (ACC 2026) - "After three doses, her lipid profile showed no improvement: TC 378 mg/dl, LDL-C 326 mg/dl, HDL-C 37 mg/dl, triglycerides 75 mg/dl...Decision-Making: Due to therapeutic failure, further options considered were monoclonal antibodies against PCSK9 (evolocumab, alirocumab) and/or bempedoic acid in combination with ezetimibe... This case series describes two high-risk patients with coronary atherosclerosis and adverse effects to conventional lipid-lowering therapies who failed to respond to inclisiran. These findings underscore the urgent need for further clinical and translational research to elucidate the biological basis of non-response, identify predictors of therapeutic failure, and optimize patient selection for inclisiran therapy."

Adverse events • Clinical • Acute Coronary Syndrome • Atherosclerosis • Cardiovascular • Coronary Artery Disease • Dyslipidemia • Hepatology • Inflammation • Metabolic Disorders • Musculoskeletal Pain

A CASE OF A DOUBLE-NONRESPONDER TO PCSK9 INHIBIOR THERAPY (ACC 2026) - "Background: The introduction of PCSK9 inhibitors (PCSK9i), including monoclonal antibodies such as evolocumab and small interfering RNA therapies such as inclisiran, has expanded lipid-lowering options for patients intolerant to statins...She had a history of statin-associated muscle symptoms and intolerance to ezetimibe... With the broader adoption of PCSK9i and inclisiran for primary and secondary prevention, rare cases of true non-response will increasingly be recognized. This case underscores the importance of considering alternative pathophysiologic mechanisms beyond known genetic variants. Future research is needed to elucidate predictors of non-response and optimize therapeutic strategies for these patients."

Clinical • Cardiovascular • Dyslipidemia • Familial Hypercholesterolemia • Genetic Disorders • Metabolic Disorders • APOB

AGGRESSIVE LIPID LOWERING IN HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA: 29 YEARS EVENT-FREE SURVIVAL AFTER PREMATURE STEMI (ACC 2026) - "He began atorvastatin 20 mg plus ezetimibe 10 mg and colesevelam (6 × 625 mg daily)...In 2018, evolocumab 140 mg q2w was added and ezetimibe stopped, dropping LDL-C to 0-20 mg/dL... Intensive lipid lowering in HeFH can alter disease trajectory. In the pre-stent era, pharmacologic LDL-C reduction became a "revascularization strategy," providing nearly thee decades of event-free survival.Early and sustained LDL-C lowering in HeFH can prevent recurrent ischemic events and promote durable clinical stability, underscoring the critical role of aggressive lipid management in secondary prevention."

Coronary Artery Disease • Dyslipidemia • Familial Hypercholesterolemia • Genetic Disorders • Heterozygous Familial Hypercholesterolemia • Metabolic Disorders

CORONARY ARTERY ECTASIA: DIVERSE PATHOPHYSIOLOGY AND IMPLICATIONS FOR TAILORED MANAGEMENT (ACC 2026) - "He was treated with statin, ezetimibe, aspirin, rivaroxaban, with plan to initiate evolocumab. Optimal care of CAE requires thoughtful evaluation and individualized therapy."

Atherosclerosis • Cardiovascular • Dyslipidemia • Metabolic Disorders • Myocardial Infarction

UTILIZATION, EXPENDITURE, AND PRICE TRENDS FOR EZETIMIBE AND NOVEL LIPID-LOWERING MEDICATIONS IN U.S. MEDICAID DRUG UTILIZATION DATA, 2002-2024 (ISPOR 2026) - "The analysis included ezetimibe (Zetia® and generic), and novel lipid-lowering medications: evolocumab (Repatha®), alirocumab (Praluent®), inclisiran (Leqvio®), bempedoic acid (Nexletol®), and evinacumab (Evkeeza®). Despite continued dominance of ezetimibe in prescription volume, Medicaid spending has shifted substantially toward high-cost NLLMs. These findings highlight a growing divergence between utilization and expenditure in Medicaid drug spending and underscore the importance of value-based pricing, outcomes-linked contracting, and formulary strategies as adoption of novel lipid-lowering agents expands."

Medicaid • Reimbursement • US reimbursement • ANGPTL3

A patient with advanced ALK-positive NSCLC at diagnosis with a follow up of >7 years and multiple lines of systemic therapy and local ablative therapy (DKK 2026) - "He was initially treated with bevacizumab, carboplatin and pemetrexed outside our institution. Due to multiple side effects the therapy was switched to pembrolizumab after the 1st cycle...The patient started alectinib in 11/2018 with rapid clinical improvement and a partial response after 6 weeks...Side effects were hypercholesterinemia (>600 gm/dl) and hypertriglyceridemia (>400 mg/dl) requiring therapy with rosuvastatin and ezetrol...NGS again showed no new on/off-target resistance pattern and he continued lorlatinib...The patient was included in the Early Access Program of NVL-655 currently available at 6 European sites. He started therapy in 06/2025 in Paris and responded in PET-CT after six weeks. He had no side effects CTC >1° and is continuing the therapy."

Clinical • IO biomarker • Metastases • Dyslipidemia • Hypertriglyceridemia • Lung Cancer • Non Small Cell Lung Cancer • Solid Tumor • ALK • EML4 • NKX2-1 • PD-L1 • TP53

Update on familial hypercholesterolemia: An expert clinical consensus from the National Lipid Association. (PubMed, J Clin Lipidol) - "A stepwise approach to optimal therapy is outlined, beginning with lifestyle interventions and pharmacotherapy with maximally tolerated statins and ezetimibe. This update incorporates newer agents, including proprotein convertase subtilisin/kexin type 9 inhibitors and bempedoic acid. Additional therapies, such as lomitapide and evinacumab for homozygous FH and lipoprotein apheresis for heterozygous and homozygous FH, are discussed. Further topics include cardiovascular imaging for risk stratification, management in specific populations and circumstances, such as planning for and during pregnancy and in pediatrics, and recognition of health disparities. This guidance equips clinicians with evidence-based strategies to improve the identification and care of patients with FH, ultimately reducing the high morbidity and mortality associated with this condition."

Journal • Atherosclerosis • Cardiovascular • Dyslipidemia • Familial Hypercholesterolemia • Genetic Disorders • Homozygous Familial Hypercholesterolemia • Metabolic Disorders • Pediatrics

Efficacy And Safety Of Enlicitide Decanoate, An Oral Macrocyclic Peptide Inhibitor Of PCSK9, Compared With Bempedoic Acid, Ezetimibe, Or Bempedoic Acid Co-administered With Ezetimibe In Statin-treated Adults With Hypercholesterolemia: Phase 3 CORALreef AddOn Trial (ACC 2026) - "Abstract is embargoed at this time."

Clinical • Late-breaking abstract • P3 data • Dyslipidemia • Metabolic Disorders

SAFETY AND EFFICACY OF SEQUENTIAL HIGH INTENSITY LIPID-LOWERING (SHILL) THERAPY FOR ATTAINMENT OF LDL-C GOAL AFTER ACUTE CORONARY SYNDROMES (ACC 2026) - "We initiated lipid-lowering with HIS and ezetimibe therapy following an ACS event & reassessed LDL-C levels after 2 weeks. If the target LDL-C goal (<55 mg/dl) was not achieved, we initiated bempedoic acid therapy (triple therapy) and further reassessed LDL-C at 4 weeks & 8 weeks... Our study demonstrates the efficacy of SHILL in achieving LDL-C goals early after ACS."

Clinical • Acute Coronary Syndrome • Cardiovascular • Hypertension

MANAGING FAMILIAL HYPERCHOLESTEROLEMIA AFTER MYOCARDIAL INFARCTION IN A PATIENT WITH A HISTORY OF RHABDOMYOLYSIS FROM A RARE METABOLIC MYOPATHY: A RARE CASE REPORT AND CLINICAL IMPLICATION (ACC 2026) - "At the time of presentation, his LDL cholesterol was elevated at 164 mg/dL while being treated with ezetimibe 10 mg daily. Selecting lipid-lowering agents for secondary prevention after ACS in patients with a history of severe rhabdomyolysis is complex. In this case, inclisiran proved to be a safe and highly effective therapeutic option, successfully reducing the patient's LDL-C level to 28 mg/dL within a three-month follow-up period without any adverse muscular events."

Case report • Clinical • Acute Coronary Syndrome • Cardiovascular • Dyslipidemia • Familial Hypercholesterolemia • Genetic Disorders • Heterozygous Familial Hypercholesterolemia • Metabolic Disorders • Myocardial Infarction • Myositis • Pulmonary Disease

ACUTE STEMI FROM CORONARY EMBOLISM IN A YOUNG MALE WITH POLYCYTHEMIA VERA (ACC 2026) - "He was started on aspirin, ticagrelor, statin, and ezetimibe; eptifibatide was stopped due to bleeding...Due to recurrent arterial events, apixaban was started, aspirin stopped, ticagrelor continued. Heart failure therapy and hydroxyurea were continued... PV can cause embolic STEMI without coronary disease. Early recognition and tailored therapy led to stable recovery."

Cardiovascular • Chronic Eosinophilic Leukemia • Chronic Kidney Disease • Congestive Heart Failure • Heart Failure • Hematological Disorders • Hypertension • Myocardial Infarction • Polycythemia Vera • Thrombosis • JAK2

WHEN LDL-C LIES - LIPOPROTEIN X MASQUERADING AS SEVERE HYPERCHOLESTEROLEMIA (ACC 2026) - "Case: A 37-year-old man with AML and prior bone marrow transplant complicated by graft-versus-host disease (GvHD) on ruxolitinib and belumosudil presented for evaluation of severe hypercholesterolemia...Statin was deferred given transaminitis, so ezetimibe and a PCSK9 inhibitor were started for lipid-lowering therapy...PCSK9i was discontinued and he was started on ursodiol to treat underlying cholestatic liver disease... Routine LDL-C values on lipid panel may misrepresent atherogenic lipoprotein burden. The Friedewald formula assumes that all triglycerides are in VLDL and that cholesterol is carried only in VLDL and LDL. In cholestatic states, this assumption breaks down: abnormal lipoprotein X (LpX), which is an ApoB-free particle enriched in unesterified cholesterol, accumulates and thereby falsely elevates calculated LDL-C."

Atherosclerosis • Bone Marrow Transplantation • Cholestasis • Dyslipidemia • Graft versus Host Disease • Hepatology • Immunology • Metabolic Disorders • APOB

POST-MI LIPID MANAGEMENT: A PRACTICE PATTERN ANALYSIS OF THERAPY ESCALATION AND MONITORING GAPS IN CARE (ACC 2026) - "Demographics, comorbidities, changes in statin dose or class, and use of second agents (e.g., ezetimibe, PCSK9 inhibitors) were recorded... Despite being a high-risk population, most patients did not achieve LDL <55 mg/dL at one year, and many lacked follow-up lipid testing. Lipid-lowering strategies were primarily limited to statin intensification with minimal use of second agents."

RAPIDLY ESCALATED LIPID-LOWERING THERAPY EFFECTIVENESS IN PLAQUE STABILIZATION IN PATIENTS WITH ELEVATED LIPOPROTEIN(A) (ACC 2026) - "Aim of this study was to assess the effectiveness of rapidly escalated lipid-lowering therapy to statin/ezetimibe/inclisiran when necessary for plaque lipid reduction using near-infrared spectroscopy (NIRS). In this study rapidly escalated triple lipid lowering therapy effectively reduced plaque lipids at 15 month-follow-up in patients with high Lp(a)."

Clinical • Atherosclerosis • Cardiovascular • Coronary Artery Disease • Dyslipidemia